149 related articles for article (PubMed ID: 36820891)
1. Validation of simplified uptake measures against dynamic Patlak K
Wijngaarden JE; Huisman MC; Jauw YWS; van Dongen GAMS; Greuter HNJM; Schuit RC; Cleveland M; Gootjes EC; Vugts DJ; Menke-van der Houven van Oordt CW; Boellaard R
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1897-1905. PubMed ID: 36820891
[TBL] [Abstract][Full Text] [Related]
2. Optimal imaging time points considering accuracy and precision of Patlak linearization for
Wijngaarden JE; Huisman MC; Pouw JEE; Menke-van der Houven van Oordt CW; Jauw YWS; Boellaard R
EJNMMI Res; 2022 Sep; 12(1):54. PubMed ID: 36065038
[TBL] [Abstract][Full Text] [Related]
3.
Miedema IHC; Wijngaarden JE; Pouw JEE; Zwezerijnen GJC; Sebus HJ; Smit E; de Langen AJ; Bahce I; Thiele A; Vugts DJ; Boellaard R; Huisman MC; Menke-van der Houven van Oordt CW
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067257
[TBL] [Abstract][Full Text] [Related]
4.
Jauw YWS; O'Donoghue JA; Zijlstra JM; Hoekstra OS; Menke-van der Houven van Oordt CW; Morschhauser F; Carrasquillo JA; Zweegman S; Pandit-Taskar N; Lammertsma AA; van Dongen GAMS; Boellaard R; Weber WA; Huisman MC
J Nucl Med; 2019 Dec; 60(12):1825-1832. PubMed ID: 31147401
[No Abstract] [Full Text] [Related]
5. Immuno-PET Imaging to Assess Target Engagement: Experience from
Menke-van der Houven van Oordt CW; McGeoch A; Bergstrom M; McSherry I; Smith DA; Cleveland M; Al-Azzam W; Chen L; Verheul H; Hoekstra OS; Vugts DJ; Freedman I; Huisman M; Matheny C; van Dongen G; Zhang S
J Nucl Med; 2019 Jul; 60(7):902-909. PubMed ID: 30733323
[TBL] [Abstract][Full Text] [Related]
6. Non-specific irreversible
Wijngaarden JE; Jauw YWS; Zwezerijnen GJC; de Wit-van der Veen BJ; Vugts DJ; Zijlstra JM; van Dongen GAMS; Boellaard R; Menke-van der Houven van Oordt CW; Huisman MC
EJNMMI Res; 2024 Feb; 14(1):18. PubMed ID: 38358425
[TBL] [Abstract][Full Text] [Related]
7. Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.
Jauw YWS; Heijtel DF; Zijlstra JM; Hoekstra OS; de Vet HCW; Vugts DJ; Verheul HM; Boellaard R; Zweegman S; van Dongen GAMS; der Houven van Oordt CWM; Lammertsma AA; Huisman MC
Mol Imaging Biol; 2018 Dec; 20(6):1025-1034. PubMed ID: 29713958
[TBL] [Abstract][Full Text] [Related]
8. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
9. Impact of Tissue Classification in MRI-Guided Attenuation Correction on Whole-Body Patlak PET/MRI.
Zhuang M; Karakatsanis NA; Dierckx RAJO; Zaidi H
Mol Imaging Biol; 2019 Dec; 21(6):1147-1156. PubMed ID: 30838550
[TBL] [Abstract][Full Text] [Related]
10. Advancing
Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
[TBL] [Abstract][Full Text] [Related]
11. Interobserver reproducibility of tumor uptake quantification with
Jauw YWS; Bensch F; Brouwers AH; Hoekstra OS; Zijlstra JM; Pieplenbosch S; Schröder CP; Zweegman S; van Dongen GAMS; Menke-van der Houven van Oordt CW; de Vries EGE; de Vet HCW; Boellaard R; Huisman MC
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1840-1849. PubMed ID: 31209514
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Analysis of Heterogeneous [
Zhuang M; Karakatsanis NA; Dierckx RAJO; Zaidi H
Mol Imaging Biol; 2019 Apr; 21(2):317-327. PubMed ID: 29956119
[TBL] [Abstract][Full Text] [Related]
13. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
14. Simplified Methods for Quantification of
Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583
[TBL] [Abstract][Full Text] [Related]
15. Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PET.
Karakatsanis NA; Zhou Y; Lodge MA; Casey ME; Wahl RL; Zaidi H; Rahmim A
Phys Med Biol; 2015 Nov; 60(22):8643-73. PubMed ID: 26509251
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.
Even AJ; Hamming-Vrieze O; van Elmpt W; Winnepenninckx VJ; Heukelom J; Tesselaar ME; Vogel WV; Hoeben A; Zegers CM; Vugts DJ; van Dongen GA; Bartelink H; Mottaghy FM; Hoebers F; Lambin P
Oncotarget; 2017 Jan; 8(3):3870-3880. PubMed ID: 27965472
[TBL] [Abstract][Full Text] [Related]
17.
Bensch F; Lamberts LE; Smeenk MM; Jorritsma-Smit A; Lub-de Hooge MN; Terwisscha van Scheltinga AGT; de Jong JR; Gietema JA; Schröder CP; Thomas M; Jacob W; Abiraj K; Adessi C; Meneses-Lorente G; James I; Weisser M; Brouwers AH; de Vries EGE
Clin Cancer Res; 2017 Oct; 23(20):6128-6137. PubMed ID: 28733442
[No Abstract] [Full Text] [Related]
18. Direct inference of Patlak parametric images in whole-body PET/CT imaging using convolutional neural networks.
Zaker N; Haddad K; Faghihi R; Arabi H; Zaidi H
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4048-4063. PubMed ID: 35716176
[TBL] [Abstract][Full Text] [Related]
19. Automated radiosynthesis of [
Wichmann CW; Poniger S; Guo N; Roselt P; Rudd SE; Donnelly PS; Blyth B; Van Zuylekom J; Rigopoulos A; Burvenich IJG; Morandeau L; Mohamed S; Nowak AK; Hegi-Johnson F; MacManus M; Scott AM
Nucl Med Biol; 2023; 120-121():108351. PubMed ID: 37224789
[TBL] [Abstract][Full Text] [Related]
20. PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
van Loon J; Even AJG; Aerts HJWL; Öllers M; Hoebers F; van Elmpt W; Dubois L; Dingemans AC; Lalisang RI; Kempers P; Brans B; Winnepenninckx V; Speel EJ; Thunnissen E; Smits KM; Boellaard R; Vugts DJ; De Ruysscher D; Lambin P
Radiother Oncol; 2017 Feb; 122(2):267-273. PubMed ID: 28012793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
